Updated: January 17, 2026
Alternatives to Yusimry If You Can't Fill Your Prescription
Author
Peter Daggett

Summarize with AI
- Other Adalimumab Biosimilars (Same Drug, Different Brand)
- Amjevita (adalimumab-atto) — Amgen
- Cyltezo (adalimumab-adbm) — Boehringer Ingelheim
- Hyrimoz (adalimumab-adaz) — Sandoz
- Hadlima (adalimumab-bwwd) — Samsung Bioepis / Organon
- Humira (adalimumab) — AbbVie (Original Brand)
- Non-Adalimumab TNF Inhibitors
- Alternatives by Condition
- Key Questions to Ask Your Doctor
If you can't fill your Yusimry prescription, you have options. Here are the best alternatives to Yusimry (adalimumab-aqvh), from other biosimilars to different drug classes.
Yusimry (adalimumab-aqvh) works well for many patients managing autoimmune conditions — but if your pharmacy can't fill your prescription, your insurance doesn't cover it, or your doctor recommends a different option, it's important to know what alternatives exist. The good news: there are several effective options, many covered at lower cost under major insurance plans.
Always talk to your doctor before switching medications — especially when it comes to biologics. But here's a clear overview of the alternatives to consider.
Other Adalimumab Biosimilars (Same Drug, Different Brand)
The simplest switch is to another FDA-approved adalimumab biosimilar. Clinical studies, including the large NOR-SWITCH trial, have shown that switching between adalimumab products is safe, with no meaningful loss of efficacy or increase in side effects. These biosimilars are approved for the same conditions as Yusimry:
Amjevita (adalimumab-atto) — Amgen
Amjevita was the first adalimumab biosimilar to launch in the US (January 2023) and holds significant market share due to a private-label agreement with OptumRx (via Nuvaila). It is an interchangeable biosimilar, meaning pharmacists can substitute it for Humira without calling your prescriber in states that allow it. Available in both low-concentration and high-concentration formulations.
Cyltezo (adalimumab-adbm) — Boehringer Ingelheim
Cyltezo was the first biosimilar to receive full FDA interchangeable designation in October 2021. It is preferred on the Express Scripts formulary (via Quallent). Available in 10 mg, 20 mg, and 40 mg syringes and a 40 mg prefilled pen. Citrate-free in the 40 mg doses.
Hyrimoz (adalimumab-adaz) — Sandoz
Hyrimoz is the preferred private-label product for CVS Caremark (Cordavis brand). It is available in both low- and high-concentration forms and in autoinjector and prefilled syringe formats. Very widely stocked at CVS pharmacies. Interchangeable designation for select presentations.
Hadlima (adalimumab-bwwd) — Samsung Bioepis / Organon
Hadlima launched in July 2023 and is an interchangeable biosimilar primarily distributed through specialty pharmacies. If your plan covers Hadlima, it may be a viable option if other biosimilars are unavailable.
Humira (adalimumab) — AbbVie (Original Brand)
Humira is the original reference biologic. It is still available, although most insurance plans now prefer biosimilars. List price is approximately $6,922 to $11,000 per month without insurance. AbbVie offers a patient assistance program (myAbbVie Assist) for eligible patients who cannot afford Humira.
Non-Adalimumab TNF Inhibitors
If your condition is one that other TNF inhibitors treat, your doctor may consider these options — each with a different mechanism profile or route of administration:
Etanercept (Enbrel, Erelzi, Eticovo) — a TNF receptor fusion protein given weekly; approved for RA, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis.
Certolizumab pegol (Cimzia) — a PEGylated TNF inhibitor; approved for RA, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, plaque psoriasis.
Golimumab (Simponi, Simponi Aria) — a monthly subcutaneous or IV TNF inhibitor; approved for RA, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis.
Alternatives by Condition
Depending on your diagnosis, your doctor may also consider medications from different drug classes:
For Rheumatoid Arthritis: JAK inhibitors such as upadacitinib (Rinvoq), tofacitinib (Xeljanz), or baricitinib (Olumiant) — oral pills that work differently from biologics.
For Plaque Psoriasis: IL-17 inhibitors (secukinumab/Cosentyx, ixekizumab/Taltz), IL-23 inhibitors (risankizumab/Skyrizi, guselkumab/Tremfya), or IL-12/23 inhibitors (ustekinumab/Stelara).
For Crohn's Disease or Ulcerative Colitis: vedolizumab (Entyvio) — a gut-selective biologic; ustekinumab (Stelara) or risankizumab (Skyrizi) for Crohn's.
Key Questions to Ask Your Doctor
Which adalimumab biosimilar does my insurance prefer?
Is switching biosimilars safe for my condition?
Are there non-biologic options I haven't tried that might qualify me for step therapy completion?
Can I get a prior authorization exception to stay on Yusimry?
If you want to try harder to locate Yusimry before switching, check out our guide on how to find Yusimry in stock near you. Or use medfinder to check which pharmacies near you can fill your prescription.
Frequently Asked Questions
Yes. Clinical studies, including the NOR-SWITCH trial, have shown that switching between adalimumab products is clinically safe with no meaningful increase in side effects or loss of efficacy. Always consult your doctor before making any change to your biologic therapy.
It depends on your insurance. CVS Caremark plans tend to prefer Hyrimoz (Cordavis private-label), Express Scripts plans prefer Cyltezo or Simlandi, and OptumRx plans prefer Amjevita. Check your plan's formulary or call your insurer to confirm.
Possibly, depending on your condition. JAK inhibitors (like upadacitinib/Rinvoq or tofacitinib/Xeljanz) are oral pills approved for rheumatoid arthritis, psoriatic arthritis, and other autoimmune conditions. Your doctor can help determine if an oral option is right for your specific case.
Yusimry is a biosimilar to Humira with no clinically meaningful differences in safety, purity, or potency — they work the same way. The main differences are price and insurance coverage. Humira remains much more expensive, though it may be preferred by some insurance plans.
Contact the manufacturer of your prescribed medication about patient assistance programs. For Yusimry, call 1-800-987-4679 or visit patient.yusimry.com. Most biologic manufacturers also offer bridge programs to help patients get medication while insurance appeals are in progress.
Medfinder Editorial Standards
Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.
Read our editorial standardsPatients searching for Yusimry also looked for:
More about Yusimry
30,552 have already found their meds with Medfinder.
Start your search today.





